Research Analysts Set Expectations for MOLN FY2024 Earnings

On March 6th, 2025, investment analysts from Leerink Partners released their earnings per share (EPS) projections for Molecular Partners AG (NASDAQ:MOLN). Analyst J. Chang anticipates that the company will report earnings of ($1.93) per share for the fiscal year 2024, which aligns with the overall market consensus.

Company Performance and Stock Details

Molecular Partners’ stock opened at $4.43 on Monday, reflecting an 11.7% decrease. Over the past 12 months, the stock has hit a low of $3.32 and a high of $12.70. Currently, the 50-day simple moving average stands at $5.09, while the 200-day simple moving average is at $5.35. The company has a market cap of $178.61 million, a negative P/E ratio of -2.06, and a beta of 1.06.

The company recently announced its quarterly earnings, revealing a loss of ($0.34) per share, which was better than the anticipated loss of ($0.45) per share by $0.11. Despite this, the company has recorded a negative return on equity of 39.31% and an extremely negative net margin of 1,043.01%.

Institutional Investor Activity

In terms of institutional investment, BVF Inc. IL has significantly increased its stake in Molecular Partners by 205.5% during the last quarter of the previous year. Following this increase, BVF Inc. now owns 1,353,968 shares after acquiring an additional 910,747 shares. This positions BVF Inc. as holding approximately 3.35% of the company's total shares, valued at $6,458,000 as of the end of the quarter. Overall, institutional investors hold 26.55% of Molecular Partners' stock.

About Molecular Partners AG

Molecular Partners AG is a clinical-stage biotechnology firm headquartered in Switzerland. The company focuses on developing designed ankyrin repeat proteins as therapeutics for cancer and viral diseases. Notable projects include MP0317, a CD40 agonist currently undergoing a Phase I clinical trial aimed at stimulating immune response within tumors, and MP0533, a unique tetra-specific T cell-engaging drug designed for the treatment of acute myeloid leukemia.

MOLN, Earnings, Analysis